← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2015Last known activity
Dec 15, 2021
Timeline
2010s
- Jun 1, 2012
ProQR Therapeutics— Founded
Drugs by trial phase (7 distinct, 13 trials)
Indications
Studied for
- Blindness
- Cystic Fibrosis
- Disease
- Epidermolysis Bullosa
- Epidermolysis Bullosa Dystrophica
- Eye Abnormalities
- Eye Diseases
- Eye Diseases, Hereditary
- Fibrosis
- Genetic Diseases, Inborn
- Leber Congenital Amaurosis
- Neurologic Manifestations
- Retinal Diseases
- Retinal Dystrophies
- Retinitis
- Retinitis Pigmentosa
- Sensation Disorders
- Usher Syndromes
- Vision Disorders
Recent trials (22)
- NCT05176717Study directorPhase 2/Phase 3Dec 15, 2021
- NCT05176717Lead sponsorPhase 2/Phase 3Dec 15, 2021
- NCT05158296Study directorPhase 2/Phase 3Dec 8, 2021
- NCT05158296Lead sponsorPhase 2/Phase 3Dec 8, 2021
- NCT05085964Lead sponsorPhase 2Sep 13, 2021
- NCT05085964Study directorPhase 2Sep 13, 2021
- NCT05052554Study directorPhase 1Aug 10, 2021
- NCT05052554Lead sponsorPhase 1Aug 10, 2021
- NCT04855045Study directorPhase 2/Phase 3Mar 23, 2021
- NCT04855045Lead sponsorPhase 2/Phase 3Mar 23, 2021
- NCT04123626Lead sponsorPhase 1/Phase 2Oct 7, 2019
- NCT04123626Study directorPhase 1/Phase 2Oct 7, 2019
- NCT03913130Lead sponsorPhase 1/Phase 2Apr 30, 2019
- NCT03913143Lead sponsorPhase 2/Phase 3Apr 4, 2019
- NCT03780257Study directorPhase 1/Phase 2Mar 6, 2019
Details
- Founded
- Leiden, NL Jun 1, 2012
- Last known activity
- Dec 15, 2021